Trumps 200% tariffs. Here's what it means for UK pharma investors

UBS warns that President Trump's proposed 200% tariffs on imported pharmaceuticals pose a "significantly negative" risk to European drugmakers, despite many large players already expanding their US manufacturing footprint. While a 12-18 month grace period is insufficient for full production relocation, potential exemptions for companies initiating US transfers offer some flexibility, though specific criteria remain unclear. The market has already priced in this threat, with European pharma majors trading at a 17% discount to historical averages, implying a 15-20% profit hit, which UBS considers reasonable given the tariff threat and ongoing pricing pressures, highlighting continued uncertainty until White House clarity.

Analysis

A renewed threat of a 200% US tariff on imported pharmaceuticals, as flagged by UBS, presents a significant headwind for European drugmakers. The proposed 12 to 18-month grace period for compliance is operationally unfeasible, as relocating commercial-scale manufacturing and securing regulatory approval typically requires four to five years. While potential exemptions for companies that have "initiated" a transfer to the US offer a possible mitigation pathway, the lack of clear criteria for what constitutes initiation creates substantial uncertainty. Several major firms, including AstraZeneca and GSK, have already announced US manufacturing expansions, which could insulate them, but the benefit depends on future policy specifics. The market has already priced in a considerable amount of this risk, with European pharmaceutical majors trading at a 17% discount to historical averages, implying a 15-20% profit impact that UBS deems reasonable under current conditions. The primary overhang remains the lack of clarity from the White House, with the upcoming Q2 earnings season expected to provide the first corporate assessments of the risk.

Key Decisions for Investors

• Investors should closely monitor any policy clarifications from the White House regarding the tariff's implementation, timeline, and especially the criteria for exemptions, as this remains the largest source of uncertainty.
• Differentiate between companies based on their existing US manufacturing footprint and announced expansion plans, as firms with proactive onshoring strategies may be better positioned to mitigate potential impacts.
• Pay close attention to management commentary during the upcoming second-quarter reporting season for guidance on risk assessment, potential earnings impact, and capital allocation adjustments in response to the tariff threat.
• Given that European pharma stocks are already trading at a 17% discount to historical averages, investors should recognize that a significant negative outcome is already priced in, suggesting potential upside if the final policy is less severe than feared.